Arterra Bioscience S.p.A. (ARBS.XMIL) Quality Score

Quality49

Growth is the primary weakness (avg 70/100). Business quality is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Export

Valuation and growth

Growth

Revenue Growth

70/100

9.4%

5–10% CAGR, steady but not exceptional

Cash Flow Growth

70/100

5.9%

5–10% CAGR, steady but not exceptional

Business Quality & Capital Allocation

Share Dilution

100/100

-2.2%

Shrinking >2%, active buybacks

Margin Trend

0/100

-4.2pp

Contracted >2pp, margin pressure

Capital Structure

100/100

-€1M

Net cash position, no leverage concern

2022

€6M

€489312

2023

€4M

€386084

2024

€3M

€356429

2025

€1M

€260351

Return on Capital

80/100

16.5%

15–20%, well above cost of capital

Customize WeightsPremiumAdjust metric weights to match your investment style.Upgrade

Related stocks: Biotechnology

PMED.XMILPiu Medical S.p.A.NIVFNewGenIvf Group LimitedPRTCPureTech Health plcNN6.XETRNanoRepro AGMAAT.XPARMaaT PharmaIVAInventiva S.A. American Depositary ReceiptANLAdlai Nortye Group Ltd. AmericanCMHSFComprehensive Healthcare Systems, Inc.

Spot a number that looks wrong? Report a data issue

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.